News

 

New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period

New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period

Nerviano, 1 February 2024     The new study “Patents and Innovation against Cancer”, just released today by the European Patent Office (EPO), reports Italy among top European nations in innovation to fight cancer. In the past 20 years close to 2 000 international patent families (IPFs) have been registered by Italian companies and research facilities. Among them, Nerviano Medical Sciences stands out as the top applicant during the 2002-2021 period.

(Click the title for the complete article)

Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery

Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery

NERVIANO Italy and PARIS France, January 8, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, and Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, today announced a collaboration agreement in AI for unprecedented kinase project.

(Click the title for the complete article)

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate

NERVIANO and MILAN, Italy, December 14, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC).

(Click the title for the complete article)

Serena Alvino Appointed as Chief Legal, Biotech & Transaction NMS Srl, Bringing Extensive Global Biopharmaceutical Experience

Serena Alvino Appointed as Chief Legal, Biotech & Transaction NMS Srl, Bringing Extensive Global Biopharmaceutical Experience

NERVIANO, IT and BOSTON, Mass, December 1, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Serena Alvino as its Chief Legal, Biotech & Transaction, effective immediately.

(Click the title for the complete article)

NMS Srl proudly takes part of the Mentoring Program 2024 organized by the Italian Chemical Society

NMS Srl proudly takes part of the Mentoring Program 2024 organized by the Italian Chemical Society

We are pleased to announce that Dr. Gianluca Papeo and Dr. Maurizio Pulici from NMS Srl are invited to be part of the permanent round table of the Pharmaceutical Division of the Italian Chemical Society (SCI) which gathers representative of the Italian Pharmaceutical industry and the Academic world to liaise their relationships under the patronage of the SCI.

(Click the title for the complete article)

Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS Srl

Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS Srl

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Tiziano Lazzaretti as its new Chief Financial Officer (CFO). Tiziano brings a wealth of leadership experience in corporate strategies, finance, and governance, acquired across diverse industries, including chemicals, pharmaceuticals and biotechnology sectors.

(Click the title for the complete article)

Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster

Nerviano Medical Sciences S.r.l. to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC 2023: Poster

NERVIANO, IT and BOSTON, Mass, October 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, reported today, initial results from the dose escalation parts of two Phase I-I/II studies for NMS-03305293 (NMS-293). As an oral, brain penetrant PARP-1 selective inhibitor, NMS-293 has shown strong antitumor activity and complete tumor regression in BRCA mutated preclinical models as a single agent. NMS-293 shows remarkable selectivity towards PARP-1 and efficiently inhibits cellular PARP activity resulting in selective antiproliferative responses on BRCA mutated cell lines. Furthermore, NMS-293 is synergistic and well tolerated in combination with temozolomide (TMZ) in both MGMT methylated and MGMT unmethylated glioblastoma mouse models. For the first time, clinical data is being presented during the poster session (Abstract 37568) at the AACR-NCI-EORCT 2023 Annual Meeting in Boston, Massachusetts. The poster will be available today on the NMS websites.

(Click the title for the complete article)

 

Welcome and Check out our new motion picture!

WATCH OUR VIDEO